成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Metabolic Enzyme/Protease Anti-infection
  3. HIV Integrase HIV
  4. Elvitegravir

Elvitegravir  (Synonyms: 埃替拉韋; GS-9137; JTK-303; D06677)

目錄號: HY-14740 純度: 99.90%
COA 產(chǎn)品使用指南 技術(shù)支持

Elvitegravir (GS-9137; JTK-303; D06677) 是一種 HIV integrase 抑制劑，作用于 HIV-1IIIB，HIV-2EHO 和 HIV-2ROD，IC50 分別為 0.7 nM，2.8 nM 和 1.4 nM。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

Elvitegravir Chemical Structure

Elvitegravir Chemical Structure

CAS No. : 697761-98-1

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥972
In-stock
5 mg ￥552
In-stock
10 mg ￥884
In-stock
50 mg ￥3464
In-stock
100 mg ￥5200
In-stock
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Elvitegravir:

    Elvitegravir purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2016;38(3):1111-20.  [Abstract]

    Arithmetic means±SEM (n=10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Elvitegravir (0.5-2.5 μg/mL).

    Elvitegravir purchased from MCE. Usage Cited in: Antimicrob Agents Chemother. 2015 Dec;59(12):7666-7670.  [Abstract]

    Effects of antiviral drugs on cellular uptake of fluorescein by BeWo cells. The cells are incubated with 1 μM fluorescein in the presence of 100 μM compounds for 10 min at 37°C.

    查看 HIV 亞型特異性產(chǎn)品:

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

    IC50 & Target

    HIV-1

     

    HIV-2

     

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    C8166 EC50
    0.00021 μM
    Compound: 1
    Antiviral activity against wild type HIV1 LAI-3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against wild type HIV1 LAI-3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 21862337]
    C8166 EC50
    0.00021 μM
    Compound: Elvitegravir
    Antiviral activity against HIV1 LAI 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 LAI 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect by MTT assay
    		[PMID: 21763149]
    C8166 EC50
    0.001 μM
    Compound: 1
    Antiviral activity against HIV1 A17 harboring reverse transcriptase Y181C mutant infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 A17 harboring reverse transcriptase Y181C mutant infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 21862337]
    C8166 CC50
    17.2 μM
    Compound: 1
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 21862337]
    C8166 CC50
    17.2 μM
    Compound: Elvitegravir
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 21763149]
    HEK-293T CC50
    > 250 μM
    Compound: Elvitegravir
    Cytotoxicity against human HEK293T cells assessed as cell growth inhibition by MTT assay
    Cytotoxicity against human HEK293T cells assessed as cell growth inhibition by MTT assay
    		[PMID: 36898139]
    HeLa CC50
    > 50 μM
    Compound: EVG
    Cytotoxicity against human HeLa-CD4-LTR-beta-gal cells after 24 hrs by ATPlite reagent based luminescence analysis
    Cytotoxicity against human HeLa-CD4-LTR-beta-gal cells after 24 hrs by ATPlite reagent based luminescence analysis
    		[PMID: 25961960]
    HeLa CC50
    > 50 μM
    Compound: 1, EVG
    Cytotoxicity against human HeLa cells expressing CD4-LTR-beta-gal after 24 hrs by ATPlite assay
    Cytotoxicity against human HeLa cells expressing CD4-LTR-beta-gal after 24 hrs by ATPlite assay
    		[PMID: 24684270]
    HeLa EC50
    0.0142 μM
    Compound: 1, EVG
    Antiviral activity against HIV1 3B infected in human HeLa cells expressing CD4-LTR-beta-gal assessed as inhibition of viral replication after 3 days by reporter gene assay
    Antiviral activity against HIV1 3B infected in human HeLa cells expressing CD4-LTR-beta-gal assessed as inhibition of viral replication after 3 days by reporter gene assay
    		[PMID: 24684270]
    MT4 EC50
    0.00037 μM
    Compound: 2, elvitegravir, GS-9137
    Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18665580]
    MT4 EC50
    0.0006 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.0007 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.0008 μM
    Compound: 1, GS-9137
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 21227550]
    MT4 EC50
    0.0009 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.001 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.0022 μM
    Compound: 3, EVG
    Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 EC50
    0.0031 μM
    Compound: 3, EVG
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 EC50
    0.012 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.015 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.018 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.033 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.05 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.059 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.077 μM
    Compound: GS-9137
    Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.9 μM
    Compound: 49
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    		[PMID: 19719237]
    MT4 CC50
    1.15 μM
    Compound: 2, elvitegravir, GS-9137
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 18665580]
    MT4 IC50
    1.3 nM
    Compound: EVG
    Inhibition of wild type HIV1 3B infected in human MT4 cells using cells pre-incubated with compound for 1 hr measured 4 days post viral infection by MTT assay
    Inhibition of wild type HIV1 3B infected in human MT4 cells using cells pre-incubated with compound for 1 hr measured 4 days post viral infection by MTT assay
    		[PMID: 22963135]
    MT4 CC50
    2.12 μM
    Compound: 1, GS-9137
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 21227550]
    MT4 EC50
    2.12 μM
    Compound: 2, GS-9137
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 20630765]
    MT4 CC50
    2.12 μM
    Compound: GS-9137
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 18541726]
    MT4 IC50
    29 nM
    Compound: EVG
    Inhibition of wild type HIV1 3B infected in human MT4 cells using cells pre-incubated with compound for 1 hr measured 4 days post viral infection in presence of 20 mg/ml HSA by MTT assay
    Inhibition of wild type HIV1 3B infected in human MT4 cells using cells pre-incubated with compound for 1 hr measured 4 days post viral infection in presence of 20 mg/ml HSA by MTT assay
    		[PMID: 22963135]
    MT4 CC50
    4 μM
    Compound: 49
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 19719237]
    MT4 CC50
    4.6 μM
    Compound: 3, EVG
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 CC50
    6.3 μM
    Compound: EVG
    Cytotoxic activity against mock-infected human MT4 cellls assessed as reduction in cell viability by MTT assay
    Cytotoxic activity against mock-infected human MT4 cellls assessed as reduction in cell viability by MTT assay
    		[PMID: 28951095]
    體外研究
    (In Vitro)

    Elvitegravir (GS-9137; JTK-303; D06677) 通過抑制 DNA 鏈轉(zhuǎn)移來阻斷 HIV-1 cDNA 的整合。 Elvitegravir 不僅對野生型毒株而且對耐藥臨床分離株都具有強大的抗 HIV 活性。 有趣的是，Elvitegravir 還顯示出對鼠白血病病毒 (MLV) 和猿猴免疫缺陷病毒 (SIV) 的抗病毒活性。 Elvitegravir 對三種實驗室 HIV 菌株顯示出有效的抗病毒活性，EC50 值在亞納摩爾到納摩爾范圍內(nèi)。 接下來，針對代表各種 HIV-1 亞型的野生型臨床分離株評估了 Elvitegravir 的活性。 Elvitegravir 抑制所有測試的 HIV-1 亞型的復制，抗病毒 EC50 范圍為 0.1 至 1.26 nM。 此外，Elvitegravir 抑制攜帶 NRTI、NNRTI 和 PI 抗性相關(guān)基因型的 HIV-1 臨床分離株的復制，對照 IN 抑制劑化合物 L-870,810 也是如此。 這些抑制劑的細胞毒性也使用 MTT 比色法測定。 在從三個獨立供體獲得的 PBMC 中，Elvitegravir 和 L-870,810 將靶細胞活力抑制 50% 的濃度平均值分別為 4.6±0.5 μM 和 2.7±0.6 μM。 因此，Elvitegravir 可以抑制多種 HIV 毒株，包括多種 HIV-1 亞型和攜帶與目前批準的抗逆轉(zhuǎn)錄病毒藥物耐藥性相關(guān)的多種突變的臨床分離株[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    447.88

    Formula

    C23H23ClFNO5
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    埃替格韋
    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細胞實驗： 

    DMSO 中的溶解度 : 233.33 mg/mL (520.97 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.2327 mL 11.1637 mL 22.3274 mL
    5 mM 0.4465 mL 2.2327 mL 4.4655 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (5.58 mM); 懸濁液; 超聲助溶

      此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.64 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.90%

    參考文獻
    Cell Assay
    [1]

    MT-2 cells (2×105 cells) are infected with HIV-1 IIIB and then cultured in the presence of 0.5 nM or 0.1 nM Elvitegravir. Cultures are incubated at 37°C until an extensive cytopathic effect (CPE) is observed, and the culture supernatant is then harvested for further passage in fresh MT-2 cells. The concentration of Elvitegravir is increased when a significant CPE is observed. At the indicated passages, proviral DNA is extracted from infected MT-2 cells and then subjected to PCR, followed by direct population-based sequencing. Susceptibility to Elvitegravir at the indicated passages is determined using the MAGI assay or p24 production[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.2327 mL 11.1637 mL 22.3274 mL 55.8185 mL
    5 mM 0.4465 mL 2.2327 mL 4.4655 mL 11.1637 mL
    10 mM 0.2233 mL 1.1164 mL 2.2327 mL 5.5819 mL
    15 mM 0.1488 mL 0.7442 mL 1.4885 mL 3.7212 mL
    20 mM 0.1116 mL 0.5582 mL 1.1164 mL 2.7909 mL
    25 mM 0.0893 mL 0.4465 mL 0.8931 mL 2.2327 mL
    30 mM 0.0744 mL 0.3721 mL 0.7442 mL 1.8606 mL
    40 mM 0.0558 mL 0.2791 mL 0.5582 mL 1.3955 mL
    50 mM 0.0447 mL 0.2233 mL 0.4465 mL 1.1164 mL
    60 mM 0.0372 mL 0.1861 mL 0.3721 mL 0.9303 mL
    80 mM 0.0279 mL 0.1395 mL 0.2791 mL 0.6977 mL
    100 mM 0.0223 mL 0.1116 mL 0.2233 mL 0.5582 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Elvitegravir
    目錄號：
    HY-14740
    需求量：